ABSTRACT Invasive aspergillosis remains a major cause of death among the immunocompromised population and those receiving long-term immunosuppressive therapy. In light of increased azole resistance, variable outcomes with existing echinocandin monotherapy and combination therapy, and persistent high mortality rates, new antifungal agents for the treatment of invasive aspergillosis are clearly needed. SCY-078 is the first-in-class triterpenoid antifungal, a novel class of glucan synthase inhibitors with broad in vitro and in vivo activity against a broad spectrum of Candida and Aspergillus species. In vitro testing of clinical strains of Aspergillus fumigatus and non-fumigatus Aspergillus strains showed that SCY-078 had potent fungistatic activity (minimum effective concentration for 90% of strains tested ϭ 0.125 g/ml) compared with the activities of amphotericin B (MIC 90 ϭ 8 g/ml) and voriconazole (MIC 90 ϭ 2 g/ml). Testing of SCY-078 in combination with isavuconazole or voriconazole demonstrated synergistic activity against the majority of the azolesusceptible strains tested, and SCY-078 in combination with amphotericin B was synergistic against the azole-susceptible strains, as well as one known resistant cyp51A mutant. SCY-078 may be an important additional antifungal for first-line or salvage monotherapy or combination treatment of invasive aspergillosis.
A spergillus species are ubiquitous fungi which for the most part are saprophytic. However, these species can be the cause of allergic reactions, including bronchopulmonary aspergillosis (quite common in asthmatics and cystic fibrosis patients) (1) or noninvasive disease, such as bronchitis or sinusitis (2) . On the other hand, invasive aspergillosis, in which the fungal spores invade the lung tissue or other internal organs, is a leading cause of death among patients receiving long-term immunosuppressive treatment for hematological malignancies or following organ transplantation (3) . Further, invasive aspergillosis is also an emerging infection among critically ill patients with predisposing conditions, such as chronic obstructive pulmonary disease (COPD), cirrhosis of the liver, or nonhematologic cancer (4) .
Antifungal therapy for invasive aspergillosis includes the azoles itraconazole (ITR), voriconazole (VOR), posaconazole (POS), and isavuconazole (ISA), as well as amphotericin B (AMB). Moreover, glucan synthesis inhibitors (echinocandins), particularly caspofungin (CAS), have been used and are approved as salvage therapy for invasive aspergillosis. VOR has been the drug of choice for the treatment of pulmonary invasive aspergillosis and is the first-line therapy recommended in recent treatment guidelines, with AMB, ISA, and CAS being recommended as alternatives or salvage therapy (5, 6) .
The suboptimal outcomes with current treatment options have prompted investigators to evaluate alternative therapeutic approaches, such as combination therapy (7), and the emergence of azole resistance among Aspergillus species has resulted in combination therapy being recommended as first-line and salvage therapy in some circumstances (8) . The emergence of azole resistance in Aspergillus fumigatus from clinical samples has been reported worldwide, although some geographical regions seem to have a higher incidence. Azole-resistant strains have been reported in patients with most clinical forms of Aspergillus infections, with an incidence of up to 8% being reported in cystic fibrosis patients, as an example (9) .
To date, clinical trials evaluating combination therapy for invasive aspergillosis have provided relatively inconclusive and sometimes conflicting results. A study by Candoni et al. evaluating the use of a combination of CAS and VOR found an 80% positive response rate for primary therapy (10), while Raad et al. showed success rates of 27% and 31% for primary and salvage therapy, respectively (11) . However, a large trial evaluating the combination of VOR and the echinocandin anidulafungin (AN) suggested a benefit of the combination versus VOR monotherapy in terms of survival, particularly in certain populations (7) . A meta-analysis conducted by Panackal et al. compared the 12-week survival rate in invasive aspergillosis patients involved in 24 published studies, encompassing 629 patients treated with combination therapy (as primary therapy in 502 patients and salvage therapy in 127 patients) and 1,204 patients treated with monotherapy (as primary therapy in 973 patients and salvage therapy in 231 patients) (12) . This analysis showed that salvage combination therapy increased the odds of 12-week survival by 80% over that with monotherapy, though the overall success rate between monotherapy and combination primary therapy was not significant (12) .
In light of the increased incidence of azole-resistant Aspergillus strains and the unacceptably high mortality rate, despite advances in antifungal therapy, new antifungal agents and therapeutic approaches for invasive aspergillosis are needed. SCY-078, currently in development by Scynexis, Inc., is a novel glucan synthase inhibitor that has oral as well as intravenous formulations. SCY-078 is a semisynthetic derivative of enfumafungin that differs structurally from echinocandins but which shares the same mechanism of action. SCY-078 has been demonstrated to have in vitro and/or in vivo activity against Aspergillus species, including azole-resistant strains (13) , as well as against Candida spp. including azole-resistant and most echinocandin-resistant strains (14) and Pneumocystis spp. (15) Additionally, SCY-078 showed high levels of activity against an uncommon CAS-resistant A. fumigatus strain (SCY-078 MIC, 0.12 g/ml; CAS MIC, Ͼ16 g/ml) (16). Further, SCY-078 demonstrated activity against ITR-resistant Aspergillus strains with a minimum effective concentration (MEC) range of 0.03 to 0.5 g/ml (12). Thus, SCY-078 shows promise as a novel drug for the treatment and prevention of invasive aspergillosis.
In this study, we report the results of susceptibility testing of SCY-078, both alone and in combination, against clinical strains of Aspergillus taken from the fungal culture collection at the Center for Medical Mycology, Cleveland, OH.
RESULTS
SCY-078 singly demonstrated potent anti-Aspergillus activity. The MEC range, MEC 50 , and MEC 90 values of SCY-078 were Ͻ0.06 to 4, Ͻ0.06, and 0.125 g/ml, respectively, against all Aspergillus isolates tested. In line with other glucan synthase inhibitors, the MIC values were 8-fold higher than the MEC values, with the MIC range, MIC 50 , and MIC 90 being Ͻ0.06 to 32, 8, and 16 g/ml, respectively, for the 50% inhibition endpoint. For the 100% inhibition endpoint, values were Ͻ0.06 to Ͼ32, 16, and 32 g/ml, respectively. There was no difference in the MEC or MIC between the different species tested, with all values being within 2 dilutions (Table 1 ). The SCY-078 minimum fungicidal concentration for 90% of isolates tested (MFC 90 ) was Ͼ32 g/ml, indicating that the antifungal activity of this new drug is fungistatic against this panel of Aspergillus strains.
The MICs of the comparator antifungals AMB and VOR were read at 100% inhibition, as indicated in the CLSI standard. The MIC range, MIC 50 , and MIC 90 values for AMB were 0.5 to Ͼ16, 4, and 8 g/ml, respectively. For VOR, the MIC range, MIC 50 , and MIC 90 values were 0.06 to Ͼ8, 0.5, and 2 g/ml, respectively ( Table 2 ). The MFC 90 was Ͼ8 g/ml for both AMB and VOR.
SCY-078 tested in combination. The combination of SCY-078 and VOR demonstrated synergistic activity against all four of the wild-type (WT) isolates tested (fractional inhibitory concentration index [FICI] range, 0.19 to 0.5). The combination of SCY-078 and VOR showed no interaction when tested against the azole-resistant A. fumigatus isolates (FICI range, 1 to 1.25; Table 3 ).
The combination of SCY-078 and AMB demonstrated synergy against all WT strains tested, (FICI range, 0.13 to 0.25) but no interaction against the azole-resistant isolate A. fumigatus MRL 28383 (FICI ϭ 1). Importantly, however, SCY-078 and AMB did demonstrate synergistic activity against the cyp51 mutant strain A. fumigatus MRL 28500 (FICI ϭ 0.28; Table 4 ).
The combination of SCY-078 and ISA demonstrated synergistic activity against all four WT isolates tested (FICI range, 0.03 to 0.5). SCY-078 and ISA demonstrated no interaction against the two azole-resistant A. fumigatus strains (MRL 28500, a cyp51 mutant, and MRL 28383; FICI range, 0.51 to 1.25) ( Table 5 ).
DISCUSSION
High rates of morbidity and mortality persist in cases of invasive aspergillosis, despite the availability of new triazole and echinocandin antifungals. In response to the need for new effective antifungal agents to prevent or treat invasive aspergillosis, SCY-078, a novel glucan synthase inhibitor, is being developed as an alternative to fungistatic activity against all species tested, with 90% of all strains being inhibited at a concentration of Յ0.125 g/ml when measured by determination of the minimum effective concentration (MEC); as with echinocandins, which have the same mechanism of action as SCY-078, this evidence of morphological damage may be better correlated with the clinical outcome than growth inhibition endpoints, though this remains to be proven through clinical use. MEC values were initially developed with CAS to reflect the fact that even though CAS was clinically active, the MIC as an endpoint did not reflect its potency. Therefore, the use of MEC for SCY-078 as well seems to be appropriate. SCY-078 MEC 90 values were 4-and 6-fold lower than the MIC 90 values of VOR and AMB, respectively. In light of the development of azole resistance in Aspergillus and the serious drug-drug interactions of azoles, along with the high toxicity rates associated with AMB, SCY-078 may prove a safer, more effective monotherapy for the treatment of Aspergillus infections.
Factors such as suboptimal outcomes (high mortality), drug-drug interactions, and azole resistance development have also led to an increased interest in the use of combination therapy to compensate for the shortcomings of monotherapy. Most of these combination studies have been based on the rationale of combining agents that have complementary mechanisms of action (17) . Thus, recent studies have combined an azole, which targets cell activity with the alteration of 14-␣-demethylase or the overexpression of drug efflux pumps (18) , with an echinocandin, which blocks the production of 1,3-␤-D-glucan, a fundamental component of the fungal cell wall (19) . However, mixed success rates have been reported with the combined use of echinocandins and azoles. Because the mutations in the FKS genes responsible for echinocandin resistance are different from those associated with resistance to enfumafungin derivatives, such as SCY-078, this new drug may demonstrate different pharmacodynamics when used in combination.
Due to the difficulty of reading the MEC in the combination plates, we opted to evaluate the interactions between various drugs using the MIC as an endpoint. MEC endpoints rely on observing morphological aberrations. In the combination plates, such changes were difficult to observe due to masking by fungal growth. Our data show that the addition of SCY-078 to ISA or VOR resulted in synergistic activity against WT A. fumigatus strains. These results are especially encouraging, in that early treatment with either combination as soon as invasive aspergillosis is suspected and before azole susceptibility is established could reduce mortality rates. Predictably, though, these combinations did not have enhanced activity against azole-resistant strains. However, addition of SCY-078 to AMB resulted in synergy not only against all WT strains tested but also against the known cyp51 mutant A. fumigatus strain. This suggests that combination therapy with SCY-078 and AMB may have greater utility in cases where azole resistance is suspected. Importantly, combination testing with SCY-078 showed no antagonism with ISA, VOR, or AMB, indicating that the addition of SCY-078 would not compromise the activity of concomitant azole or polyene therapy.
Overall, SCY-078 demonstrated potent activity against A. fumigatus and nonfumigatus Aspergillus isolates. This novel antifungal would be a much needed addition to the armamentarium available for the prevention and treatment of invasive aspergillosis. An important advantage would be the availability of SCY-078 in both oral and intravenous formulations, which would provide many more options for both monotherapy and combination therapy. Randomized clinical trials are needed in order to fully characterize the effectiveness of SCY-078. 
